Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic
Executive Summary
Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.